The FDA approved the treatment through the prescription-to-OTC switch process.
The FDA has approved ivermectin 0.5% (Sklice; Arbor Pharmaceuticals LLC) lotion as an OTC treatment for head lice through the process of prescription (Rx)-to-OTC switch, according to a news release.
Ivermectin lotion, 0.5% was first approved by the FDA as a prescription drug for this indication in patients 6 months of age and older in February 2012.
Ivermectin 0.5% lotion is a single-use lotion for the topical treatment of head lice. As a result of this announcement, the treatment will no longer be available as a prescription drug, but rather will be offered over the counter.
There are an estimated 6 to 12 million cases of head lice in children ages 3 to 11 each year in the United States, according to the CDC, with cases most abundant in children in preschool, child care, and elementary school.
Rx-to-OTC switches occur when data show that the drug is safe and effective when used as directed in the proposed labeling; manufacturers must also prove that consumers can understand how to use the drug safely and effectively without the help of a health care professional.
“The Rx-to-OTC switch process aims to promote public health by increasing consumer access to drugs that would otherwise only be available by prescription,” said Theresa Michele, MD, acting director of the Office of Nonprescription Drugs in the FDA’s Center for Drug Evaluation and Research. “Today’s approval expands access to another effective topical treatment for the thousands of people with head lice.”
Reference:
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.